Hellstrand, Kristoffer

Publishing since 1989 (Dinosaur)

Has published 69 publications in 22 years

Number of publications published per year by Hellstrand, Kristoffer. (Source : PubMed)

Distribution of publications types for Hellstrand, Kristoffer. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Westin J, Hellstrand K, Dhillon AP, Lagging M. Are FoxP3(+) cells involved in hyporesponsiveness to interferon/ribavirin therapy in chronic hepatitis C?  J. Viral Hepat.  2010  
•  Alsiö A, Christensen PB, Färkkilä M, Langeland N, Buhl MR, Pedersen C, Mørch K, Haagmans BL, Westin J, Hellstrand K, Norkrans G, Lagging M. Nonresponder patients with hepatitis C virus genotype 2/3 infection: a question of low systemic interferon concentrations?  Clin. Infect. Dis.  2010;50;4  
•  Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Norkrans G, Westin J, Söderholm J, Hellstrand K, Lagging M. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.  Hepatology  2009  
•  Romero AI, Thorén FB, Aurelius J, Askarieh G, Brune M, Hellstrand K. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML.  Scand. J. Immunol.  2009;70;3  
•  Brune M, Romero AI, Hellstrand K. Histamine dihydrochloride and interleukin-2 in acute myeloid leukemia--background and results.  Inflamm. Res.  2009;58 Suppl 1  
•  Lagging M, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Dhillon AP, Alsiö A, Hellstrand K, Westin J, Christensen P, Leutscher P, Norkrans G. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.  Hepatology  2008;48;2  
•  Lagging M, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Dhillon AP, Alsiö A, Hellstrand K, Westin J, Norkrans G. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection.  Hepatology  2008;47;6  
•  Lindh M, Hellstrand K, Norkrans G. Wider indications for treatment of chronic hepatitis B?  J. Viral Hepat.  2008;15;3  
•  Westin J, Ydreborg M, Islam S, Alsiö A, Dhillon AP, Pawlotsky JM, Zeuzem S, Schalm SW, Ferrari C, Neumann AU, Hellstrand K, Lagging M. A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection.  Scand. J. Gastroenterol.  2008;43;1  
•  Middleton M, Hauschild A, Thomson D, Anderson R, Burdette-Radoux S, Gehlsen K, Hellstrand K, Naredi P. Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.  Ann. Oncol.  2007;18;10  

[ See timeline ] [ See all publications ]